Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of mavorixafor in WHIM syndrome with open-label extension
2019-001153-10Phase 3Active
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in WHIM syndrome (WHIM) and Immunogenetic disorder comparing Mavorixafor with Placebo (2 arms). Primary endpoint: Time above ANC threshold. Started Oct 2019; status: active.
02
Drugs
mavorixafor
03
Conditions
WHIM syndrome (WHIM)Immunogenetic disorder
Beyond the preview
Go deeper on 2019-001153-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001153-10.